We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Read MoreHide Full Article
Perrigo Company plc (PRGO - Free Report) is expected to report fourth-quarter and full-year 2018 results after market close on Feb 27.
Perrigo’s earnings history has been quite impressive with the company surpassing expectations in all the last four quarters, with the average beat being 4.6%. In the last reported quarter, the company delivered a positive surprise of 3.81%.
Shares of the company have lost 34.6% in the past six months compared with the industry’s decrease of 1.7%.
Let’s see how things are shaping up for the upcoming announcement.
Factors Likely to Influence Results
Perrigo is currently focused on the growth strategy of Consumer Healthcare Americas segment through switching of prescription drugs to over-the-counter (“OTC”) brands and expansion of store brand solution. The company launched the OTC version of several drugs in the past couple of quarters, which are likely to boost the company’s top line in the soon-to-be reported quarter.
In September, the FDA approved a stored brand OTC equivalent of J&J’s (JNJ - Free Report) multi-symptom relief drug, Imodium. In August, the company entered into an agreement with Merck (MRK - Free Report) to gain exclusive rights to the OTC version of the latter’s allergy drug, Nasonex nasal spray. Moreover, the launch of the OTC version of heartburn drug, Omeprazole delayed release in April is likely to boost sales this quarter.
However, the company also settled patent litigations related to several drugs, which may increase expenses in the fourth quarter.
The new products in the Consumer Healthcare Americas business and Consumer Health Care International segment saw improved sales in the third quarter – a trend expected to continue this quarter. However, declining sales at animal health business may offset the gain from new products.
On its third-quarter earnings call, Perrigo lowered its sales and earnings outlook for 2018 on lower expectations for Prescription Pharmaceuticals (Rx) segment. Sales in the Rx segment has been on a declining trend so far 2018 and we expect sales to be lower in the soon-to-be-reported quarter.
Meanwhile, the ongoing restructuring initiatives and operating expense discipline are anticipated to cushion the company’s bottom line. In August, the company announced its plan to spin-off its Rx business to create value for shareholders and focus on expanding its leading consumer business. The segment has been facing declining sales due to delay in launch of products and price erosion.
On the earnings call, we expect the company to provide an update on the progress of the plan to spin-off Rx business as well as the benefits arising from focusing on OTC market.
Earnings Whispers
Our proven model does not conclusively show that Perrigo is likely to beat estimates this reporting cycle. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (96 cents) and the Zacks Consensus Estimate (98 cents) is -2.12%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Perrigo carries a Zacks Rank #4 (Sell).
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here is a biotech stock that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Perrigo Company plc (PRGO - Free Report) is expected to report fourth-quarter and full-year 2018 results after market close on Feb 27.
Perrigo’s earnings history has been quite impressive with the company surpassing expectations in all the last four quarters, with the average beat being 4.6%. In the last reported quarter, the company delivered a positive surprise of 3.81%.
Shares of the company have lost 34.6% in the past six months compared with the industry’s decrease of 1.7%.
Let’s see how things are shaping up for the upcoming announcement.
Factors Likely to Influence Results
Perrigo is currently focused on the growth strategy of Consumer Healthcare Americas segment through switching of prescription drugs to over-the-counter (“OTC”) brands and expansion of store brand solution. The company launched the OTC version of several drugs in the past couple of quarters, which are likely to boost the company’s top line in the soon-to-be reported quarter.
In September, the FDA approved a stored brand OTC equivalent of J&J’s (JNJ - Free Report) multi-symptom relief drug, Imodium. In August, the company entered into an agreement with Merck (MRK - Free Report) to gain exclusive rights to the OTC version of the latter’s allergy drug, Nasonex nasal spray. Moreover, the launch of the OTC version of heartburn drug, Omeprazole delayed release in April is likely to boost sales this quarter.
However, the company also settled patent litigations related to several drugs, which may increase expenses in the fourth quarter.
The new products in the Consumer Healthcare Americas business and Consumer Health Care International segment saw improved sales in the third quarter – a trend expected to continue this quarter. However, declining sales at animal health business may offset the gain from new products.
On its third-quarter earnings call, Perrigo lowered its sales and earnings outlook for 2018 on lower expectations for Prescription Pharmaceuticals (Rx) segment. Sales in the Rx segment has been on a declining trend so far 2018 and we expect sales to be lower in the soon-to-be-reported quarter.
Meanwhile, the ongoing restructuring initiatives and operating expense discipline are anticipated to cushion the company’s bottom line. In August, the company announced its plan to spin-off its Rx business to create value for shareholders and focus on expanding its leading consumer business. The segment has been facing declining sales due to delay in launch of products and price erosion.
On the earnings call, we expect the company to provide an update on the progress of the plan to spin-off Rx business as well as the benefits arising from focusing on OTC market.
Earnings Whispers
Our proven model does not conclusively show that Perrigo is likely to beat estimates this reporting cycle. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (96 cents) and the Zacks Consensus Estimate (98 cents) is -2.12%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Perrigo carries a Zacks Rank #4 (Sell).
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Perrigo Company plc Price and EPS Surprise
Perrigo Company plc Price and EPS Surprise | Perrigo Company plc Quote
Stock to Consider
Here is a biotech stock that you may want to consider as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Mallinckrodt has an Earnings ESP of +5.36% and a Zacks Rank #2. The company is scheduled to report results on Feb 26. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>